CANCERPLEX® is a large-gene panel consisting of >400 cancer-associated genes for the detection of genetic abnormalities underlying cancer with 95->99% sensitivity and specificity at low allelic fractions, determinations of Microsatellite Instability (MSI-H) and Tumor Mutation Burden (TMB-H) status to identify patients who are most likely to respond to immune checkpoint inhibition, and for the presence of HPV/EBV viral integration which may impact treatment decisions. All data generated from sequencing at the local laboratory are processed through our high-quality, high-performance analytics platform, which combines state-of-the-art, industry-leading bioinformatics tools for variant detection with GENEKEEPER® , our proprietary software and knowledgebase for variant interpretation. To date, we have profiled thousands of patients with CANCERPLEX and are proud to have reported clinically actionable variants in 93% of these patients1.

CANCERPLEX WORKFLOW

CANCERPLEX COVERS

N

FDA-Approved & Investigational Drug Targets

N

Microsatellite Instability & Tumor Mutation Burden

N

Therapeutic Targetable Pathways

N

Drug Resistance Genes

CANCERPLEX ANALYTICAL PERFORMANCE

 

Sensitivity

Specificity

Single Nucleotide Variants

99.5%

>99%

Insertions and Deletions

>99%

>99%

Copy Number Variation gain (>2.5 fold change)

98.1%

>99%

Copy Number Variation loss (<0.75 fold change)

>99%

>99%

Structural Variants

>99%

>99%

Microsatellite Instability

>99%

>99%

Viral Integration

>99%

>99%

*10% MAF detection limitation

CANCERPLEX  REPORT

The report contains a list of potential therapies targeting the genomic changes unique to the patient, including
N

FDA-approved therapies in patient’s cancer type

N

Clinical trials enrolling patients with the cancer type

N

FDA-approved therapies in other cancer types

CANCERPLEX  ADVANTAGES

High success rate

Quality results obtained from as little as 50ng DNA in >94% tissue samples

Fast turnaround time

Only 7-10 business days

Comprehensive molecular profile

  • All types of possible genomic changes (e.g., SNVs, indels, CNVs and fusions)
  • The patient’s likelihood to respond to immunotherapy (i.e., tumor mutational burden and MSI)
  • Cancer-related viruses

Variety of tissue types

◊ Solid tumors   ◊ Pleural effusions   ◊ Fine needle aspirates

Unparalleled clinical actionability

93% of patients matched with targeted  therapies

Dedicated real-time support

  • KEW updates its gene panels and GENEKEEPER database to stay current and actionable
  • KEW provides one-on-one support to oncologists to help make the process go smoothly and to answer any questions they may have about the test results

Learn more about how comprehensive genomic profiling can benefit you.

Molecular Laboratory

Expand your current internal precision medicine program.

Learn More

Physicians

Send samples directly to KEW for sequencing and clinical report.

Learn More

Patients & Caregivers

See how comprehensive genomic profiling can benefit you.

Learn More

  1. Eifert C, Pantazi A , Sun R, Xu J, Cingolani P, Heyer J, Russell M, Lvova M, Ring J, Tse J, Lyle S, Protopopov A.   Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. PERSONALIZED MEDICINE. Vol.14,NO.4

Call us

855.225.4068

Email

kewcustomercare@kewinc.com

Location

840 Memorial Drive, 4th Floor Cambridge, MA 02139